

Biotin anti-mouse TER-119/Erythroid Cells Antibody

Catalog# / Size	116203 / 50 µg 116204 / 500 µg
Clone	TER-119
Regulatory Status	RUO
Other Names	Ly-76
Isotype	Rat IgG2b, κ
Description	The TER-119 antigen is a 52 kD glycophorin A-associated protein, also known as Ly-76. TER-119 is an erythroid-specific antigen expressed on early proerythroblasts to mature erythrocytes, but not on erythroid colony-forming cells (BFU-E, blast-forming unit erythroid, or CFU-E, colony-forming unit erythroid).

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Day-14 fetal liver cells from a C57BL/6 mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	The TER-119 antibody is useful for distinguishing erythrocytes and cells in the erythroid lineage. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ , Western blotting ¹ , complement-mediated cytotoxicity ³ , and immunohistochemical staining of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections. Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 116253-116258).

Application References

1. Kina T, *et al.* 2000. *Br. J. Haematol.* 109:280. (IP, WB)
2. Vannucchi AM, *et al.* 2000. *Blood* 95:2559.
3. Maraskovsky E, *et al.* 1996. *J. Exp. Med.* 184:1953. (CMCD)
4. Grisendi S, *et al.* 2005. *Nature* 437:147. (FC)
5. Bourdeau A, *et al.* 2007. *Blood* 109:4220.
6. Chappaz S, *et al.* 2007. *Blood* 110:3862. (FC)
7. Heuser M, *et al.* 2007. *Blood* 110:1639. (FC)
8. Gough SM, *et al.* 2014. *Cancer Discov.* 4:564. [PubMed](#)

Product Citations

1. Drobek A, *et al.* 2015. *J Immunol.* 195: 3416 - 3426. [PubMed](#)
2. Hu J, *et al.* 2019. *Am J Transl Res.* 3.043055556. [PubMed](#)
3. Grigsby SM, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
4. Davis FM, *et al.* 2020. *J Immunol.* 2503:204. [PubMed](#)
5. Bouchareychas L, *et al.* 2021. *iScience.* 24(8):102847. [PubMed](#)
6. Kim S, *et al.* 2020. *Immunity.* 53(4):759-774.e9. [PubMed](#)

7. Geiger SS, *et al.* 2021. Nature Communications. 12(1):2745. [PubMed](#)
8. Han X, *et al.* 2017. Int J Mol Sci. 10.3390/ijms18050942. [PubMed](#)
9. Domingues AF, *et al.* 2020. Elife. 9:e51754. [PubMed](#)
10. Zhu C, *et al.* 2018. Sci Rep. 5.113194444. [PubMed](#)
11. Tanimura N *et al.* 2018. Developmental cell. 46(5):581-594 . [PubMed](#)
12. Wu J, *et al.* 2022. Nat Commun. 13:7321. [PubMed](#)
13. Florentin J, *et al.* 2022. Front Immunol. 13:882484. [PubMed](#)
14. Schloss MJ, *et al.* 2022. Nat Immunol. 23:605. [PubMed](#)
15. Guo F, *et al.* 2022. Front Immunol. 13:833100. [PubMed](#)
16. Lv X, *et al.* 2022. Acta Pharm Sin B. 12:735. [PubMed](#)
17. Tian M, *et al.* 2020. Proc Natl Acad Sci U S A. 117:7929. [PubMed](#)
18. Preglej T, *et al.* 2020. JCI Insight. 5(4):. [PubMed](#)
19. Riether C, *et al.* 2021. Cell Reports. 34(4):108663. [PubMed](#)
20. Krueger PD, *et al.* 2021. Immunity. 54(4):687-701.e4. [PubMed](#)
21. Postat J *et al.* 2018. Immunity. 49(4):654-665 . [PubMed](#)
22. Yu VWC *et al.* 2016. Cell. 167(5):1310-1322 . [PubMed](#)
23. Gutiérrez-Gutiérrez Ó, *et al.* 2021. EMBO Rep. 22:e52905. [PubMed](#)
24. Matsumoto R, *et al.* 2021. Front Pharmacol. 12:715752. [PubMed](#)
25. Iturri L, *et al.* 2021. Immunity. . [PubMed](#)
26. de Mingo Pulido , *et al.* 2021. Immunity. 54(6):1154-1167.e7. [PubMed](#)
27. Browning LM, *et al.* 2020. Cell Rep. 33:108219. [PubMed](#)
28. Fu R, *et al.* 2019. Nat Commun. 10:3210. [PubMed](#)
29. Álvaro de Mingo Pulido *et al.* 2018. Cancer cell. 33(1):60-74 . [PubMed](#)
30. Hodzic D, *et al.* 2022. PLoS Biol. 20:e3001811. [PubMed](#)
31. Yang X, *et al.* 2020. Blood Sci. 2:89. [PubMed](#)
32. Pokrovskii M, *et al.* 2020. EMBO J. 39:e104159. [PubMed](#)
33. Hinterbrandner M, *et al.* 2021. JCI Insight. 6:e151797. [PubMed](#)
34. Verena Sigl *et al.* 2017. Cell research. 26(7):761-74 . [PubMed](#)
35. Liu X, *et al.* 2021. eLife. 0.4166666666666667. [PubMed](#)
36. Yamamoto K, *et al.* 2021. Cell Reports. 36(8):109576. [PubMed](#)
37. Li Q *et al.* 2018. Immunity. 48(2):258-270 . [PubMed](#)
38. Mann M, *et al.* 2018. Cell Rep. 25:2992. [PubMed](#)
39. Zhao M, *et al.* 2019. Cell Rep. 26:652. [PubMed](#)
40. Davis FM, *et al.* 2019. Arterioscler Thromb Vasc Biol. 39:2353. [PubMed](#)
41. Fukushima T, *et al.* 2019. Cell Rep. 29:4144. [PubMed](#)
42. Zong L, *et al.* 2021. NPJ Aging Mech Dis. 7:25. [PubMed](#)
43. Liu YY, *et al.* 2020. Chin Med J (Engl). 133:1688. [PubMed](#)
44. Olsson A, *et al.* 2016. Nature. 10.1038/nature19348. [PubMed](#)
45. Dey A *et al.* 2019. The EMBO journal. 38(7) pii: e100293. [PubMed](#)
46. Kimball A, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:1102. [PubMed](#)
47. She L, *et al.* 2021. JCI Insight. 6:e143509. [PubMed](#)
48. Sitaraman S, *et al.* 2021. JCI Insight. 6: . [PubMed](#)
49. Paiva RS, *et al.* 2021. Eur J Immunol. 51:1968. [PubMed](#)
50. Kurkewich J, *et al.* 2016. PLoS One. 11: 0161468. [PubMed](#)
51. Jassinskaja M, *et al.* 2021. Cell Reports. 34(12):108894. [PubMed](#)
52. Levine LS, *et al.* 2021. Immunity. 54(4):829-844.e5. [PubMed](#)
53. Paiva RA, *et al.* 2021. Cell Reports. 35(2):108967. [PubMed](#)
54. Shimokawa C *et al.* 2017. Immunity. 46(5):863-874 . [PubMed](#)
55. Wang L, *et al.* 2021. Cancer Immunol Res. 9:348. [PubMed](#)
56. Kawakami R, *et al.* 2021. Immunity. 54(5):947-961.e8. [PubMed](#)
57. Hurrell BP, *et al.* 2019. Cell Rep. 29:4509. [PubMed](#)
58. Yu VWC, *et al.* 2017. Cell. 168:944. [PubMed](#)
59. Kimball AS *et al.* 2019. Immunity. 51(2):258-271 . [PubMed](#)
60. Onodera T, *et al.* 2019. J Immunol. 203:3282. [PubMed](#)
61. Xu L *et al.* 2017. Immunity. 47(3):538-551 . [PubMed](#)
62. Cheng HW, *et al.* 2019. Nat Commun. 10:1739. [PubMed](#)
63. Chen X *et al.* 2017. Cell stem cell. 21(6):747-760 . [PubMed](#)
64. Haase C, *et al.* 2022. Nat Methods. 19:1622. [PubMed](#)
65. Lopez DA, *et al.* 2022. Cell Rep. 41:111677. [PubMed](#)
66. Chatterjee S, *et al.* 2014. PLoS One. 9:87858. [PubMed](#)
67. Ludwik KA, *et al.* 2021. STAR Protocols. 2(1):100270. [PubMed](#)
68. Derecka M, *et al.* 2020. Nat Immunol. 26:21. [PubMed](#)
69. Peraki I, Palis J, and Mavrothalassitis G. 2017. Mol Cell Biol. 10.1128/MCB.00183-17. [PubMed](#)
70. Greenwald AC, *et al.* 2019. J Exp Med. 216:215. [PubMed](#)
71. Hulsmans M *et al.* 2017. Cell. 169(3):510-522 . [PubMed](#)
72. Dong S, *et al.* 2021. Nature. 591:117. [PubMed](#)
73. Progzky F, *et al.* 2021. Nature. 599:125. [PubMed](#)
74. Zhu H, *et al.* 2020. J Bone Miner Res. 35:698. [PubMed](#)
75. Milner JJ, *et al.* 2020. Immunity. 52(5):808-824.e7. [PubMed](#)
76. Frodermann V, *et al.* 2019. Nat Med. 25:1761. [PubMed](#)
77. Schoeler K, *et al.* 2019. FEBS J. 10.1111/febs.14934. [PubMed](#)
78. Lin C, *et al.* 2022. Nat Commun. 13:6869. [PubMed](#)
79. Onodera T, *et al.* 2021. Immunity. 54:2385. [PubMed](#)
80. Lebert-Ghali C, *et al.* 2016. Blood. 127: 87-90. [PubMed](#)
81. Trefzer A, *et al.* 2021. Cell Reports. 34(6):108748. [PubMed](#)
82. Sitaraman S, *et al.* 2019. Sci Rep. 9:12509. [PubMed](#)
83. Alameh MG, *et al.* 2021. Immunity. 54:2877. [PubMed](#)
84. Löönd F, *et al.* 2022. STAR Protoc. 3:101438. [PubMed](#)
85. Yi W, *et al.* 2021. Cell Reports. 34(13):108922. [PubMed](#)
86. Andersen L, *et al.* 2020. Cell Reports. 29(13):4447-4459.e6.. [PubMed](#)

87. Kubota S, *et al.* 2019. Nat Commun. 10:1653. [PubMed](#)
88. Wang C, *et al.* 2018. J Clin Invest. 128:3872. [PubMed](#)
89. Chen Z, *et al.* 2019. J Exp Med. 216:152. [PubMed](#)
90. Sevin M, *et al.* 2018. Nat Commun. 9:1431. [PubMed](#)
91. Galle-Treger L, *et al.* 2020. J Allergy Clin Immunol. 145:502. [PubMed](#)
92. Galle-Treger L, *et al.* 2019. Nat Commun. 10:713. [PubMed](#)
93. Balzano M *et al.* 2019. Cell reports. 26(12):3257-3271 . [PubMed](#)
94. Goldstein JM *et al.* 2019. Cell reports. 27(4):1254-1264 . [PubMed](#)
95. Yang BH, *et al.* 2020. Cell Reports. 27(12):3629-3645.e6.. [PubMed](#)
96. Akkaya B, *et al.* 2017. J Immunol Methods. 441:67. [PubMed](#)
97. Zhai X, *et al.* 2021. Sci Adv. 7:eabk0490. [PubMed](#)
98. Gamrekelashvili J, *et al.* 2021. Bio Protoc. 11:e4007. [PubMed](#)
99. Kanemaru K, *et al.* 2015. PLoS One. 10: 0144436. [PubMed](#)
100. Frohner IE, *et al.* 2020. Cell Rep. 30:3171. [PubMed](#)
101. Bagadia P, *et al.* 2019. Nat Immunol. 20:1174. [PubMed](#)
102. Vasamsetti SB, *et al.* 2018. Immunity. 49:93. [PubMed](#)
103. Duarte D, *et al.* 2018. Cell Stem Cell. 22:64. [PubMed](#)
104. Lehrke MJ, *et al.* 2021. Elife. 10: [PubMed](#)
105. Fujii T, *et al.* 2021. Bone Res. 9:4. [PubMed](#)
106. Gu VW, *et al.* 2021. Stem Cell Reports. 16:106. [PubMed](#)
107. Zeis P, *et al.* 2020. Immunity. 53:775. [PubMed](#)
108. Nasarre P, *et al.* 2021. Cancers (Basel). 13: . [PubMed](#)
109. Alexander K, *et al.* 2016. Immunol Cell Biol. 95:7-16. [PubMed](#)
110. Christin JR, *et al.* 2020. Cell Reports. 31(10):107742. [PubMed](#)
111. Kimball AS, *et al.* 2020. Thromb Haemost. 120:289. [PubMed](#)
112. Adachi Y, *et al.* 2019. Nat Commun. 10:3883. [PubMed](#)
113. Maroni G, *et al.* 2019. Int J Mol Sci. 20. [PubMed](#)
114. Nagashima H *et al.* 2019. Immunity. 51(4):682-695 . [PubMed](#)
115. Buffolo M, *et al.* 2019. Cell Rep. 29:270. [PubMed](#)
116. Fu NY, *et al.* 2018. Dev Cell. 47:629. [PubMed](#)
117. Hasenberg M, *et al.* 2011. PLoS One. 6:e17314. [PubMed](#)
118. Schönberger K, *et al.* 2022. STAR Protoc. 3:101408. [PubMed](#)
119. Zhang MH, *et al.* 2020. Front Immunol. 11:560. [PubMed](#)
120. Yokomizo-Nakano T, *et al.* 2020. Cancer Res. 80:2523. [PubMed](#)
121. He M, *et al.* 2020. Cell Metabolism. 31(3):580-591. [PubMed](#)
122. Wolock SL, *et al.* 2019. Cell Rep. 28:302. [PubMed](#)
123. Bajaan S, *et al.* 2022. iScience. 25:103732. [PubMed](#)
124. Koide S, *et al.* 2022. iScience. 25:103603. [PubMed](#)
125. Miyauchi K, *et al.* 2021. Nat Commun. 12:3789. [PubMed](#)
126. Michel A, *et al.* 2013. J Immunol. 90:5534. [PubMed](#)
127. Lefkopoulos S, *et al.* 2020. Immunity. 53(5):934-951.e9. [PubMed](#)
128. Zhang C, *et al.* 2018. Cell Res. 28:323. [PubMed](#)
129. Park DS, *et al.* 2019. PLoS Comput Biol. 15:e1006913. [PubMed](#)
130. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
131. Mohrin M, *et al.* 2021. Aging Cell. 20:e13313. [PubMed](#)
132. Anderson DA, *et al.* 2022. J Exp Med. 219:.. [PubMed](#)
133. Rai S, *et al.* 2022. Nat Commun. 13:5346. [PubMed](#)
134. Riedel SS, *et al.* 2021. Molecular Cell. 81(11):2332-2348.e9. [PubMed](#)
135. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
136. Matsuzaki Y, *et al.* 2015. Biomed Rep. 1: 91 - 97. [PubMed](#)
137. Säwen P *et al.* 2018. eLife. 7 pii: e41258. [PubMed](#)
138. Luo H, *et al.* 2019. Cell Rep. 26:945. [PubMed](#)
139. Heyde A, *et al.* 2021. Cell. 184(5):1348-1361.e22. [PubMed](#)
140. Huang X, *et al.* 2021. Immunity. . [PubMed](#)
141. Li ZG, *et al.* 2020. Chin Med J (Engl). 1943:133. [PubMed](#)
142. O'Boyle C, *et al.* 2020. Int J Stroke. 0.746527778. [PubMed](#)
143. Bae S, *et al.* 2021. Cell Reports. 35(11):109264. [PubMed](#)
144. Young K, *et al.* 2021. Cell Stem Cell. . [PubMed](#)
145. Zysset D, *et al.* 2016. Nat Commun. 7:13151. [PubMed](#)
146. Seong J, *et al.* 2018. Development. 145:14. [PubMed](#)
147. Johnson JL *et al.* 2018. Immunity. 48(2):243-257 . [PubMed](#)
148. Celas DP, *et al.* 2022. STAR Protoc. 3:101464. [PubMed](#)
149. Liao YC, *et al.* 2021. Front Immunol. 12:743030. [PubMed](#)
150. Davis FM, *et al.* 2021. J Exp Med. 218:.. [PubMed](#)

RRID

AB_313704 (BioLegend Cat. No. 116203)
 AB_313705 (BioLegend Cat. No. 116204)

Antigen Details

Structure	Associated with glycoprotein A, 52 kD
Distribution	Early proerythroblast to mature erythrocyte, but not BFU-E and CFU-E
Cell Type	Erythrocytes

Biology Area


Immunology

Antigen References

1. Kina T, *et al.* 2000. *Br. J. Haematol.* 109:280.
2. Ikuta K, *et al.* 1990. *Cell* 62:863.
3. Osawa M, *et al.* 1996. *Weir's Handbook of Experimental Immunology*. Vol. 2 pp. 66.1-66.5.

Gene ID[104231](#)**Related Protocols**[Cell Surface Flow Cytometry Staining Protocol](#)**Other Formats**

APC anti-mouse TER-119/Erythroid Cells, Biotin anti-mouse TER-119/Erythroid Cells, FITC anti-mouse TER-119/Erythroid Cells, PE anti-mouse TER-119/Erythroid Cells, PE/Cyanine5 anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 488 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 647 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 700 anti-mouse TER-119/Erythroid Cells, PE/Cyanine7 anti-mouse TER-119/Erythroid Cells, APC/Cyanine7 anti-mouse TER-119/Erythroid Cells, PerCP anti-mouse TER-119/Erythroid Cells, PerCP/Cyanine5.5 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 421™ anti-mouse TER-119/Erythroid Cells, Pacific Blue™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 605™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 510™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 605™ anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 785™ anti-mouse TER-119/Erythroid Cells, TotalSeq™-A0122 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 750 anti-mouse TER-119/Erythroid Cells, TotalSeq™-B0122 anti-mouse TER-119/Erythroid Cells, TotalSeq™-C0122 anti-mouse TER-119/Erythroid Cells, Ultra-LEAF™ Purified anti-mouse TER-119/Erythroid Cells, Spark Blue™ 550 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 810 anti-mouse TER-119/Erythroid Cells, Spark NIR™ 685 anti-mouse TER-119/Erythroid Cells Antibody

Product Data

C57BL/6 bone marrow cells were stained with biotinylated TER-119 (filled histogram) or biotinylated rat IgG2b, κ isotype control (open histogram) and then detected with Sav-PE.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587